Study guide
2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals
Key Takeaways Explain This Topic AI
Parenteral products must be sterile, pyrogen-free, and particulate-controlled; intrathecal and epidural injectables must be strictly preservative-free.
Hypertonic parenteral solutions exceeding 900 mOsm/L 900\text{ mOsm/L} 900 mOsm/L require central venous administration to prevent peripheral vein phlebitis and thrombosis.
Terminal moist heat sterilization (autoclaving at 121 ∘ C 121^\circ\text{C} 12 1 ∘ C ) denatures microbial proteins and is validated using Geobacillus stearothermophilus biological indicators.
Bacterial endotoxins (LPS from Gram-negative bacteria) are thermostable and pass through 0.22 μ m 0.22\ \mu\text{m} 0.22 μ m filters, quantified via the Limulus Amebocyte Lysate (LAL) assay.
Biopharmaceutical protein drugs require non-ionic surfactants to prevent interfacial aggregation and non-reducing disaccharides (sucrose, trehalose) as lyoprotectants during freeze-drying.
Last updated: August 2026
Parenteral Administration Routes and Physiological Constraints
Parenteral drug administration bypasses the gastrointestinal tract and the body's primary protective epithelial barriers, demanding stringent standards for sterility, pyrogenicity, osmolarity, and particulate matter.
Routes and Anatomical Constraints
Intravenous (IV): Bolus or continuous infusion directly into the venous circulation. Provides immediate 100 % 100\% 100% systemic bioavailability without an absorption phase. Requires aqueous solutions; specialized O/W emulsions (e.g., propofol, IV lipid emulsions) must maintain droplet sizes < 0.5 μ m < 0.5\ \mu\text{m} < 0.5 μ m to prevent capillary fat embolism.
Intramuscular (IM): Injected into deep skeletal muscle (deltoid, ventrogluteal, vastus lateralis). Volumes typically limited to ≤ 2 mL \le 2\text{ mL} ≤ 2 mL (deltoid) or ≤ 4 to 5 mL \le 4\text{ to }5\text{ mL} ≤ 4 to 5 mL (gluteal). Can accommodate aqueous solutions, suspensions, and oily depot formulations (e.g., haloperidol decanoate, medroxyprogesterone acetate).
Subcutaneous (SC): Injected into the subcutaneous adipose tissue. Maximum injection volume is typically ≤ 1.5 mL \le 1.5\text{ mL} ≤ 1.5 mL . Avoids muscle tissue; suitable for self-administration of small molecules (heparin) and biologics (insulin, monoclonal antibodies).
Intrathecal (IT) and Epidural: Injected directly into the subarachnoid cerebrospinal fluid (CSF) space (IT) or outside the dura mater (epidural).
CRITICAL MANDATORY REQUIREMENT: Neuraxial preparations must be STRICTLY PRESERVATIVE-FREE . Common preservatives (e.g., benzyl alcohol, parabens, phenol, benzalkonium chloride) cause direct neurotoxicity, irreversible chemical arachnoiditis, paraplegia, and death. Preserved multidose vials must NEVER be administered via the spinal route.
Neonatal Warning: Benzyl alcohol in neonates causes fatal "gasping syndrome" (severe metabolic acidosis, CNS depression, gasping respirations, and cardiovascular collapse) due to immature hepatic glycine conjugation.
Osmolality, Tonicity, and Osmotic Calculations
Normal human blood serum osmolality ranges from 285 to 295 mOsm/kg 285\text{ to }295\text{ mOsm/kg} 285 to 295 mOsm/kg (roughly isosmotic with 0.9 % 0.9\% 0.9% w/v sodium chloride solution). Tonicity Effects on Erythrocytes:
- |-- Isotonic Solution (~290 mOsm/L) --> Normal RBC morphology (equilibrium)
- |-- Hypotonic Solution (< 250 mOsm/L) --> Water enters RBCs --> Swelling & LYSIS (Hemolysis)
- |-- Hypertonic Solution (> 350 mOsm/L) --> Water exits RBCs --> Shrinkage (CRENATION)
- Osmolarity and Route Selection
Peripheral IV Lines: Solutions with osmolarity between 250 and 900 mOsm/L 250\text{ and }900\text{ mOsm/L} 250 and 900 mOsm/L can generally be infused peripherally.
Central Venous Lines: Solutions exceeding > 900 mOsm/L > 900\text{ mOsm/L} > 900 mOsm/L (e.g., total parenteral nutrition [TPN], 3 % 3\% 3% or 5 % 5\% 5% hypertonic NaCl, ≥ 20 % \ge 20\% ≥ 20% Dextrose) must be infused via a central venous catheter into the superior vena cava, where high-volume blood flow ( 2 − 3 L/min 2-3\text{ L/min} 2 − 3 L/min ) rapidly dilutes the hypertonic fluid to prevent severe phlebitis, endothelial damage, and venous thrombosis.
Sodium Chloride Equivalent ( E E E -Value) Method
The E E E -value represents the mass of sodium chloride (in grams) that produces the same osmotic effect as 1.0 gram 1.0\text{ gram} 1.0 gram of the drug: E = 17 ⋅ L iso MW E = 17 \cdot \frac{L_{\text{iso}}}{\text{MW}} E = 17 ⋅ MW L iso
Where L iso L_{\text{iso}} L iso is the isosmotic freezing point depression constant (typically 3.4 3.4 3.4 for univalent-univalent electrolytes, 1.9 1.9 1.9 for non-electrolytes) and MW \text{MW} MW is the molecular weight.
To calculate required NaCl for isotonicity in volume V V V (mL): Total NaCl required = 0.009 × V \text{Total NaCl required} = 0.009 \times V Total NaCl required = 0.009 × V NaCl contribution from drug = Mass of drug (g) × E \text{NaCl contribution from drug} = \text{Mass of drug (g)} \times E NaCl contribution from drug = Mass of drug (g) × E NaCl to add = ( 0.009 × V ) − [ Mass of drug × E ] \text{NaCl to add} = (0.009 \times V) - [\text{Mass of drug} \times E] NaCl to add = ( 0.009 × V ) − [ Mass of drug × E ]
Sterilization and Depyrogenation Technologies
Sterilization destroys or eliminates all viable microorganisms (bacteria, fungi, bacterial endospores, and viruses) from a product.
Sterilization Method Mechanism Operating Conditions Standard Biological Indicator Applications & Limitations
Moist Heat (Autoclave) Protein denaturation and coagulation Saturated steam: 121 ∘ C 121^\circ\text{C} 12 1 ∘ C for 15 min 15\text{ min} 15 min at 15 psi 15\text{ psi} 15 psi (or 134 ∘ C 134^\circ\text{C} 13 4 ∘ C for 3 − 4 min 3-4\text{ min} 3 − 4 min ) Geobacillus stearothermophilus spores Aqueous solutions in sealed containers, surgical steel. Cannot sterilize non-aqueous oils or heat-labile drugs.
Dry Heat Microbial oxidation Convection oven: 160 − 170 ∘ C 160-170^\circ\text{C} 160 − 17 0 ∘ C for ≥ 2 hours \ge 2\text{ hours} ≥ 2 hours Bacillus atrophaeus spores Anhydrous oils, powders, glassware. Depyrogenation requires ≥ 250 ∘ C \ge 250^\circ\text{C} ≥ 25 0 ∘ C for ≥ 30 minutes \ge 30\text{ minutes} ≥ 30 minutes .
Gas (Ethylene Oxide) Alkylation of microbial nucleic acids and proteins 30 − 60 ∘ C 30-60^\circ\text{C} 30 − 6 0 ∘ C , 40 − 80 % RH 40-80\%\text{ RH} 40 − 80% RH , followed by extensive aeration Bacillus atrophaeus spores Heat-sensitive medical devices, plastics. Toxic gas residues require prolonged desorption.
Ionizing Radiation DNA strand scission via free radical generation Gamma rays ( 60 Co ^{60}\text{Co} 60 Co ) or Electron beam: 25 kGy 25\text{ kGy} 25 kGy dose Bacillus pumilus spores Bulk single-use medical supplies, pre-filled syringes. High capital equipment cost.
Membrane Filtration Physical retention of particles by size exclusion 0.22 μ m 0.22\ \mu\text{m} 0.22 μ m sterile membrane filter (PES, PVDF, nylon) Brevundimonas diminuta (challenge ≥ 10 7 CFU/cm 2 \ge 10^7\text{ CFU/cm}^2 ≥ 1 0 7 CFU/cm 2 ) Heat-labile solutions, biologics. Does NOT remove viruses or pyrogens. Filter integrity verified by Bubble Point Test .
Pyrogens, Bacterial Endotoxins, and Particulate Control
Bacterial Endotoxins: Lipopolysaccharides (LPS) derived from the outer cell membrane of Gram-negative bacteria (e.g., E. coli , Pseudomonas ). The hydrophobic Lipid A core mediates biological toxicity.
Properties: Highly water-soluble, non-volatile, thermostable (survives standard autoclaving at 121 ∘ C 121^\circ\text{C} 12 1 ∘ C ), and passes freely through 0.22 μ m 0.22\ \mu\text{m} 0.22 μ m sterilizing filters.
Clinical Reaction: Triggers macrophage activation, interleukin-1 (IL-1) and TNF- α \alpha α release, producing high fevers, systemic vasodilation, disseminated intravascular coagulation (DIC), and irreversible septic shock.
Testing: The Limulus Amebocyte Lysate (LAL) assay (utilizing an aqueous extract of horseshoe crab amebocytes) undergoes enzymatic gel-clotting or chromogenic color change in the presence of endotoxin.
Endotoxin Limits ( K / M K/M K / M ): For non-intrathecal parenterals, K = 5.0 EU/kg/hr K = 5.0\text{ EU/kg/hr} K = 5.0 EU/kg/hr ; for intrathecal injectables, the limit is strictly K = 0.2 EU/kg/hr K = 0.2\text{ EU/kg/hr} K = 0.2 EU/kg/hr .
Particulate Matter Standards: Parenterals must meet USP standards for sub-visible particles ( ≥ 10 μ m \ge 10\ \mu\text{m} ≥ 10 μ m and ≥ 25 μ m \ge 25\ \mu\text{m} ≥ 25 μ m ) via light obscuration tests. Ampoules must always be withdrawn using a 5 -micron filter needle 5\text{-micron filter needle} 5 -micron filter needle to eliminate glass particulates before injection.
Biopharmaceuticals and Advanced Drug Delivery Systems
Biologics (monoclonal antibodies, recombinant cytokines, therapeutic enzymes) are large, complex macromolecules whose biological activity depends on intricate tertiary and quaternary protein structures.
Protein Degradation Pathways
Physical Instability:
Denaturation: Unfolding of native 3D conformation into disordered polypeptide chains.
Aggregation: Self-association of unfolded monomers into sub-visible and visible aggregates. Aggregated proteins are highly immunogenic and can induce neutralizing anti-drug antibodies (ADAs).
Adsorption: Hydrophobic surface binding to glass vials or IV infusion tubing (e.g., insulin adhering to PVC lines). Formulations incorporate non-ionic surfactants ( Polysorbate 20 or Polysorbate 80 ) to saturate interfaces and prevent adsorption.
Chemical Instability: Deamidation of asparagine/glutamine residues, oxidation of methionine/cysteine residues, peptide bond hydrolysis, and disulfide scrambling.
Lyophilization (Freeze-Drying) Science
Lyophilization removes water by sublimation, stabilizing moisture-sensitive proteins for extended storage:
Freezing: Solution is frozen below its eutectic point or glass transition temperature ( T g ′ T_g' T g ′ ).
Primary Drying (Sublimation): Ice sublimates directly to vapor under high vacuum ( 0.05 − 0.2 mbar 0.05-0.2\text{ mbar} 0.05 − 0.2 mbar ) below the formulation collapse temperature ( T c T_c T c ).
Secondary Drying (Desorption): Temperature is elevated to desorb residual bound water to < 2 % < 2\% < 2% moisture.
Cryoprotectants & Lyoprotectants: Non-reducing disaccharides ( sucrose , trehalose ) replace water hydrogen bonds at the protein surface ( "water replacement hypothesis" ) and vitrify into a protective amorphous glass matrix that prevents conformational collapse.
Bulking Agents: Mannitol or glycine provide structural elegance and mechanical stability to the lyophilized cake.
Advanced Nanocarriers and Targeted Delivery
Liposomes: Spherical vesicles composed of synthetic phospholipid bilayers enclosing an aqueous core. Pegylated (stealth) liposomes (e.g., liposomal doxorubicin / Doxil ) evade clearance by the reticuloendothelial system (RES), prolonging circulation half-life from minutes to ∼ 55 hours \sim 55\text{ hours} ∼ 55 hours and accumulating in tumor tissue via the Enhanced Permeability and Retention (EPR) effect, while markedly reducing cardiotoxicity.
Lipid Nanoparticles (LNPs): Complex four-component lipid assemblies containing ionizable cationic lipids (to bind negatively charged mRNA and facilitate endosomal escape), helper phospholipids, cholesterol, and PEGylated lipids (used in mRNA COVID-19 vaccines).
Antibody-Drug Conjugates (ADCs): A targeted monoclonal antibody linked covalently via a stable linker to a potent antineoplastic payload (e.g., trastuzumab emtansine / T-DM1 ), selectively delivering cytotoxic agents directly to antigen-expressing tumor cells.